Overview

All Sanguine study protocols and their resulting samples, which include all Sanguine at-home and apheresis collection programs, are conducted under an Institutional Review Board (IRB). Sanguine operates under an electronic informed consent process which executes 21 CFR part 11 compliant e-signatures, and Sanguine systems interacting with study participant information are HIPAA-compliant.

Sanguine’s LeukoLot™ bulk PBMCs provide researchers with high-yield (billions of cells per donor), high-viability peripheral blood mononuclear cells (PBMCs) collected from a leukopak and isolated within one day to ensure optimal functionality. After the cells are isolated, washed and counted, PBMCs are aliquoted and stored using CryoStor® CS10 freezing media. Bulk PBMCs include donor demographics, verified-conditions via donor electronic medical records, and infectious disease testing.Our bulk PBMCs contain a diverse population of immune cells, including T cells, B cells, NK cells, monocytes, and dendritic cells—making them ideal for immunology research, drug development, and cell-based assays.

Well-characterized PBMCs for Alzheimer’s research supports studies on neurodegeneration, amyloid and tau pathology, and therapeutic development to advance understanding and treatments for cognitive decline.